OR WAIT null SECS
, Inc.,an integrated oncology company, announced that it has played a role in the development of 42 novel cancer therapies approved by the US Food and Drug Administration (FDA).
Tasigna (nilotinib) capsules, a medicine developed by Novartis Pharmaceuticals Corporation, was the most recent therapy to benefit from clinical trials conducted in part by physicians and patients within the US Oncology Research network. The drug, which was recently approved by the FDA, is for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) in chronic phase.
US Oncology is affiliated with 500 sites of care throughout the nation and its network treats about 850,000 patients a year.